Immunomodulation exerted by galectins: a land of opportunity in rare cancers

Rare cancers represent only 5% of newly diagnosed malignancies. However, in some cases, they account for up to 50% of the deaths attributed to cancer in their corresponding organ. Part of the reason is that treatment options are generally quite limited, non-specific, and very often, only palliative....

Full description

Bibliographic Details
Main Authors: Laura Díaz-Alvarez, Georgina I. López-Cortés, Erandi Pérez-Figueroa
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1301025/full